Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab vs Sunitinib in Untreated Advanced Renal Cell Carcinoma (Phase III, Japan)
jRCT2080222931Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Atezolizumab + Bevacizumab with Sunitinib (2 arms). Started Aug 2015; status: completed.
02
Drugs
atezolizumabbevacizumabsunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2080222931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222931.